The Core Distinction

Eczema (atopic dermatitis) and psoriasis are both chronic inflammatory skin conditions, but they are mechanistically distinct. Getting the diagnosis right is critical — because the approaches differ:

Eczema (Atopic Dermatitis)Psoriasis
Primary defectFilaggrin gene mutation → barrier dysfunction → IgE sensitisationT-cell dysregulation → keratinocyte hyperproliferation → accelerated turnover
AppearanceWeepy, crusting, intensely itchy; flexural creasesWell-defined plaques with silver scale; extensor surfaces
Age of onsetUsually infancy/childhood; often persistsAny age; typically late teens onward
Trigger mechanismBarrier disruption → allergen penetration → immune responseStress, injury (Koebner), infection, certain medications

Eczema: The Barrier-First Protocol

The fundamental defect in atopic dermatitis is a filaggrin gene (FLG) mutation — filaggrin is a structural protein essential for stratum corneum barrier integrity. Without adequate filaggrin, the barrier becomes permeable to allergens and irritants, triggering the Th2-dominant immune response that characterises atopic dermatitis.

  • First priority: Restore and maintain the barrier continuously
  • Apply ceramide-rich emollients immediately after bathing ("soak and seal")
  • Use only fragrance-free, hypoallergenic products — fragrance is the primary eczema sensitiser
  • Avoid known triggers: dust mites, pet dander, certain food allergens in sensitised individuals
  • Medical management: Topical corticosteroids (TCS) for flares; dupilumab (IL-4/IL-13 blocker) for moderate-severe — requires dermatologist

Psoriasis: Managing Hyperproliferation

Psoriatic skin turns over in 3–5 days (vs 28 days for normal skin) — driven by activated T-cells releasing TNF-α, IL-17, and IL-23. This creates the thick, scaly plaques characteristic of the condition.

  • Keratolytics: Salicylic acid (2–10%) physically removes scale build-up
  • Vitamin D analogues (Rx): Calcipotriol inhibits keratinocyte proliferation and promotes differentiation
  • Coal tar: Anti-proliferative and anti-inflammatory; messy but effective for scalp psoriasis
  • Biologics (Rx): Secukinumab, ixekizumab (anti-IL-17), ustekinumab (anti-IL-23) — for moderate-severe systemic disease

Both conditions benefit from: Stress management (cortisol exacerbates both), consistent emollient use between flares, fragrance-free skincare, and identifying individual triggers through a structured elimination approach.

For the gut-skin connection in eczema, see Gut-Skin Axis. For the stress-skin link, see Psychodermatology.